Cargando…

Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia

Detalles Bibliográficos
Autor principal:	Davidson, Michael H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486198/ https://www.ncbi.nlm.nih.gov/pubmed/26137571 http://dx.doi.org/10.1016/j.ebiom.2015.03.004

Ejemplares similares

Does FFAR4 Agonism have Therapeutic Potential in Cardiometabolic Disease?
por: Lay, Abigail C
Publicado: (2021)

D2/D3 Receptor Agonism: Paving the Way for a New Therapeutic Target for Taste Disorders in Parkinson’s Disease and Other Conditions?
por: Mantovani, Elisa, et al.
Publicado: (2022)

The brain strikes back: Hypothalamic targets for peripheral CB(1) receptor inverse agonism
por: Cota, Daniela
Publicado: (2017)

Harnessing MerTK agonism for targeted therapeutics
por: Kedage, Vivekananda, et al.
Publicado: (2019)

Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
por: Samuelsson, O., et al.
Publicado: (2013)

Prostaglandin I(2) Receptor Agonism for Proteinuria and Diabetes: Good for the Goose and Good for the Gander?
por: Menon, Madhav C., et al.
Publicado: (2016)

The therapeutic potential of GLP‐1 receptor biased agonism
por: Jones, Ben
Publicado: (2021)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
por: Campbell, Jonathan E.
Publicado: (2020)

Inverse agonism and its therapeutic significance
por: Khilnani, Gurudas, et al.
Publicado: (2011)

Kelussia odoratissima Mozaffarian and dyslipidemia
por: Dehghan Shahreza, Fatemeh
Publicado: (2015)

Beta-2 adrenergic receptor agonism alters astrocyte phagocytic activity and has potential applications to psychiatric disease
por: Bowen, Ellen R., et al.
Publicado: (2023)

A New Treatment Strategy for Diabetic Dyslipidemia?
por: Kothari, Vishal, et al.
Publicado: (2020)

Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice
por: van Eenige, Robin, et al.
Publicado: (2021)

Molecular mechanism of agonism and inverse agonism in ghrelin receptor
por: Qin, Jiao, et al.
Publicado: (2022)

Biased agonism
por: Kenakin, Terry
Publicado: (2009)

Agonizing Hedgehog
por: Weitzman, Jonathan B
Publicado: (2002)

Agon : ballet for twelve dancers
por: Stravinsky, Igor, 1882-1971
Publicado: (1957)

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
por: Sachs, Stephan, et al.
Publicado: (2023)

Central obesity & dyslipidemia in HIV patients on antiretroviral therapy
por: Kumar, Sanjay, et al.
Publicado: (2018)

The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus
por: Chatziralli, Irini P.
Publicado: (2017)

Bilirubin: A Potential Biomarker and Therapeutic Target for Diabetic Nephropathy
por: Hull, Travis D., et al.
Publicado: (2014)

Transgelin in bladder cancer: A potential biomarker and therapeutic target
por: Li, Wei-Ming, et al.
Publicado: (2019)

Novel therapeutic targets and agents for pediatric dyslipidemia
por: Sunil, Bhuvana, et al.
Publicado: (2021)

CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
por: Charpentier, Maud, et al.
Publicado: (2023)

LRRK2-NFATc2 Pathway Associated with Neuroinflammation May Be a Potential Therapeutic Target for Parkinson’s Disease
por: Wang, Youcui, et al.
Publicado: (2021)

Dyslipidemia in Obesity: Mechanisms and Potential Targets
por: Klop, Boudewijn, et al.
Publicado: (2013)

Identifying genes that regulate bone remodeling as potential therapeutic targets
por: Krane, Stephen M.
Publicado: (2005)

Developments in the Role of Endothelin-1 in Atherosclerosis: A Potential Therapeutic Target?
por: Sutton, Greg, et al.
Publicado: (2019)

Woman with agonal breathing
por: Hsu, Chien‐Te, et al.
Publicado: (2023)

The future of EPAC-targeted therapies: agonism versus antagonism
por: Parnell, Euan, et al.
Publicado: (2015)

Potential alteration of COVID-19 by beta-mercaptoethanol
por: Click, Robert E
Publicado: (2020)

Dual protein kinase C alpha and beta inhibitors and diabetic kidney disease: a revisited therapeutic target for future clinical trials
por: Koya, Daisuke
Publicado: (2013)

Connexin43 Modulation of Osteoblast/Osteocyte Apoptosis: A Potential Therapeutic Target?
por: Civitelli, Roberto
Publicado: (2008)

Vitamin D as a Potential Therapeutic Target and Prognostic Marker for Colorectal Cancer
por: Bintintan, Vasile V.
Publicado: (2018)

tRF-1001: A potential therapeutic target for ocular neovascular diseases
por: Cingaram, Pradeep Reddy
Publicado: (2023)

αTAT1: a potential therapeutic target in cancer?
por: Chien, J-Y, et al.
Publicado: (2016)

Beta-adrenergic signaling, a novel target for cancer therapy?
por: Schuller, Hildegard M.
Publicado: (2010)

Targeted IgMs agonize ocular targets with extended vitreal exposure
por: Chen, Yvonne, et al.
Publicado: (2020)

MD-2 as a possible therapeutic target for atherosclerosis
por: Chen, Shuang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qttrkkdd8ekdpbaplmbldm7h7r